Access to High-Resolution Anoscopy
Expanding access to high-resolution anoscopy is critical to preventing anal cancer, as HRA is the gold-standard method for detecting and treating precancerous lesions before they become invasive disease. Anal cancer disproportionately affects people living with HIV, men who have sex with men, transgender women, and communities of color—groups that already face significant barriers to care. When access to HRA is limited, those at highest risk are least likely to receive timely screening and treatment, leading to avoidable late-stage diagnoses and worse outcomes.
In 2025, the WSMA House of Delegates adopted Resolution C-3 – Expanding Access to High-Resolution Anoscopy. In this webinar, Bob Geise, MD, will explain who needs this screening and when.
Originally recorded April 3, 2026.
Release date: April 10, 2026.
Expiration date: April 9, 2029.
About the Presenter
Bob Geise, MD, is a co-author of the 2025 resolution and the section chief of infectious diseases and travel medicine at Virginia Mason Franciscan Health.
Learning Objectives
- Review populations at higher risk for anal cancer.
- Discuss screening strategies and how to interpret results appropriately.
- Review appropriate uses for anal pap smears and when to refer for high-resolution anoscopy.
Resources
- Presenter slides
- IANS Anal Cancer Prevention Screening ToolKit
- IANS Whom and How to Screen
- HIV Clinical Guidelines Now Recommend High Resolution Anoscopy as Part of Anal Cancer Screening Program for People with HIV
- Anal Cancer Screening and Prevention—A New Era, Limited by Access to High-Resolution Anoscopy
- A Guide to High Resolution Anoscopy (HRA)
Claim CME credit
To claim CME credit, watch or listen to the podcast, then complete the evaluation. Once the evaluation is completed, it will be forwarded to the CME credit claim form.